explore -WSS

explore

author：Wikipedia 2025-10-01 00:45:45 - browse：7467

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Study: Black kids more likely to die after surgery than white kids

leisure time

WSS

Pancreatic cancer is often deadly, but new discoveries are raising hope

Fentanyl is making it harder to start addiction treatment

Scientists uncover potential path to treating deadly childhood tumor

Fentanyl is making it harder to start addiction treatment

Bird flu surveillance in wastewater gets boost from consortium

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

focus

explore

focus

Sports medicine is finally prioritizing gender equality

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Supreme Court strikes down use of affirmative action

Republican states more likely to report Covid vaccine side effects

Medical records are filled with copy

Harvard scientists, with Google, unveil the most detailed brain map ever

In age of alternative facts, a scholarly course on calling out crap

ASCO eve: Let’s set the table for this year's meeting

Dobbs anniversary: the lost opportunity of abortion as health care

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

leisure time

People with mental disorders often marry others with same

Alzheimer's risk factor APOE4 may be a distinct form of the disease

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Republican states more likely to report Covid vaccine side effects

For longer

hotspot

leisure time

hotspot

leisure time